Latest News and Press Releases
Want to stay updated on the latest news?
-
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Glacier Media Inc. (TSX: GVC) (“Glacier” or the “Company”) reported revenue and earnings for the year ended December 31, 2025. ...
-
HAMILTON, BERMUDA, March 19, 2026 – DHT Holdings, Inc. (NYSE:DHT) (the “Company”) has filed its 2025 annual report on Form 20-F with the U.S. Securities and Exchange Commission (the “SEC”). The...
-
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in...
-
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003...
-
"Stairway to Seven" launching from Firefly's Space Launch Complex 2 at Vandenberg Space Force Base in California on March 11, 2026. CEDAR PARK, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Firefly...
-
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in...
-
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Gemini Space Station, Inc. (“Gemini”) (NASDAQ: GEMI) today reported its fourth quarter and full year 2025 financial results in a shareholder letter and...
-
Full Year Net Sales of $161.7 million including Proprietary Brand Sales of $44.0 million Full Year Proprietary Brand Penetration Increased to 32.8% up from 24.2% in the prior year Full Year GAAP...
-
Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general...
-
– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque...